Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
|
LA JOLLA PHARMACEUTICAL CO (LJPC)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 | Dec-31-20 | Sep-30-20 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Total revenues | 10.5 | 10.4 | 12.2 | 13.3 | 16.1 | 34.1 | 11.0 | 9.1 |
| Revenue growth | -34.3% | -69.5% | 11.5% | 46.8% | 176.6% | 349.7% | 51.0% | 59.0% |
| Cost of goods sold | 1.7 | 2.2 | 2.1 | 2.9 | 2.2 | 6.3 | 3.8 | 2.5 |
| Gross profit | 8.8 | 8.3 | 10.1 | 10.4 | 13.9 | 27.8 | 7.1 | 6.6 |
| Gross margin | 83.9% | 79.2% | 82.6% | 78.4% | 86.6% | 81.5% | 65.2% | 72.6% |
| Selling, general and administrative [+] | 9.8 | 10.3 | 9.0 | 8.6 | 9.0 | 8.8 | 9.1 | 12.5 |
| General and administrative | | | 9.0 | | | | 9.1 | |
| Other selling, general and administrative | | | | | | | | |
| Research and development | 0.2 | 0.0 | 1.1 | 1.3 | 1.1 | 1.6 | 1.4 | 3.6 |
| EBITDA [+] | -0.7 | -1.6 | 0.4 | 0.9 | 4.2 | 17.9 | -3.0 | -8.9 |
| EBITDA growth | -115.7% | -109.1% | -114.7% | -110.6% | -135.9% | -290.5% | -87.6% | -65.3% |
| EBITDA margin | -6.3% | -15.7% | 3.6% | 7.1% | 26.2% | 52.5% | -27.1% | -98.2% |
| Depreciation | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 |
| EBITA | -0.7 | -1.7 | 0.4 | 0.9 | 4.2 | 17.9 | -3.0 | -9.2 |
| EBITA margin | -6.4% | -15.9% | 3.3% | 6.9% | 26.1% | 52.4% | -27.4% | -101.7% |
| Amortization of intangibles | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 |
| EBIT [+] | -1.1 | -2.0 | 0.0 | 0.5 | 3.8 | 17.5 | -3.4 | -9.5 |
| EBIT growth | -128.2% | -111.7% | -100.6% | -105.5% | -130.4% | -267.2% | -86.5% | -64.5% |
| EBIT margin | -10.1% | -19.6% | 0.2% | 3.9% | 23.6% | 51.2% | -31.0% | -105.0% |
| Interest expense, net [+] | 2.4 | 2.4 | 2.4 | 2.7 | 2.7 | 2.6 | 2.6 | 2.5 |
| Interest expense | 2.4 | 2.4 | 2.4 | 2.7 | 2.7 | 2.6 | 2.6 | 2.5 |
| Interest income | | | 0.0 | | | | 0.0 | 0.0 |
| Other income (expense), net [+] | 5.9 | 4.5 | 6.2 | 0.0 | 2.6 | -0.4 | 2.6 | 0.3 |
| Other | -0.5 | 0.5 | 1.1 | 0.0 | 0.1 | -0.4 | 0.4 | 0.3 |
| Pre-tax income | 2.5 | 0.0 | 3.8 | -2.2 | 3.7 | 14.4 | -3.5 | -11.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.7% | 33.3% | 0.0% | | 0.0% | 0.1% | 0.0% | 0.0% |
| Net income | 2.5 | 0.0 | 3.8 | -2.3 | 3.7 | 14.4 | -3.5 | -11.8 |
| Net margin | 23.3% | 0.0% | 30.9% | -17.0% | 23.2% | 42.2% | -31.8% | -129.6% |
| |
| Basic EPS [+] | $0.10 | $0.00 | $0.14 | ($0.08) | $0.14 | $0.53 | ($0.13) | ($0.43) |
| Growth | -28.7% | -100.0% | -207.9% | -80.9% | -123.8% | -266.7% | -86.3% | -60.0% |
| Diluted EPS [+] | $0.08 | $0.00 | $0.11 | ($0.08) | $0.11 | $0.42 | ($0.13) | ($0.43) |
| Growth | -29.8% | -100.0% | -186.6% | -80.9% | -119.1% | -233.7% | -86.3% | -60.0% |
| |
| Shares outstanding (basic) [+] | 25.3 | 26.2 | 27.4 | 27.5 | 27.5 | 27.4 | 27.3 | 27.4 |
| Growth | -7.7% | -4.6% | 0.4% | 0.5% | 0.5% | 0.7% | 0.8% | 0.9% |
| Shares outstanding (diluted) [+] | 32.1 | 32.9 | 34.2 | 27.5 | 34.2 | 34.2 | 27.3 | 27.4 |
| Growth | -6.2% | -3.7% | 25.1% | 0.5% | 25.2% | 25.5% | 0.8% | 0.9% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|